Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma.
Shi X, Yan L, Shang J, Kang L, Yan Z, Jin S, Zhu M, Chang H, Gong F, Zhou J, Chen G, Pan J, Liu D, Zhu X, Tang F, Liu M, Liu W, Yao F, Yu L, Wu D, Fu C.
Shi X, et al.
Am J Hematol. 2022 May;97(5):537-547. doi: 10.1002/ajh.26486. Epub 2022 Feb 9.
Am J Hematol. 2022.
PMID: 35114022
Free article.
Clinical Trial.